Albireo, An Ipsen Company
Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.
-
New drug could buy time for kids with rare liver disease
Disease control OngoingThis study tests an experimental drug called odevixibat in children with biliary atresia who have already had Kasai surgery. The goal is to see if the drug can delay or prevent the need for a liver transplant and improve survival. About 254 children will receive either odevixibat…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New hope for kids with rare liver disease: drug may delay transplant
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of odevixibat in children with biliary atresia, a rare liver disease. The main goal is to see if the drug helps children stay alive without needing a liver transplant. About 180 children who completed a previous study will t…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 11, 2026 20:51 UTC